FAXDC2 inhibits the proliferation and invasion of human liver cancer HepG2 cells
The reprogramming of lipid metabolism serves an important role in occurrence and development of liver cancer. Fatty acid hydroxylase domain containing 2 (FAXDC2) is a hydroxylase involved in the synthesis of cholesterol and sphingomyelin and downregulated in various types of cancer. There are no rep...
Gespeichert in:
Veröffentlicht in: | Experimental and therapeutic medicine 2024-01, Vol.27 (1), p.27, Article 27 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 27 |
container_title | Experimental and therapeutic medicine |
container_volume | 27 |
creator | Peng, Zhilin Xu, Siting Zhang, Qing Yang, Xueting Yuan, Wuzhou Wang, Yuequn Li, Yongqing Zhu, Ping Wu, Xiushan Jiang, Zhigang Li, Fang Fan, Xiongwei |
description | The reprogramming of lipid metabolism serves an important role in occurrence and development of liver cancer. Fatty acid hydroxylase domain containing 2 (FAXDC2) is a hydroxylase involved in the synthesis of cholesterol and sphingomyelin and downregulated in various types of cancer. There are no reports on the relationship between FAXDC2 and liver carcinogenesis. The present study used multiple portals and publicly available tools to explore its correlation with liver cancer. The results showed that the expression of FAXDC2 decreased in liver cancer and the methylation level near the promoter increased. Patients with liver cancer and with low expression of FAXDC2 had a poor prognosis. Gain of function and loss of function strategies were performed to evaluate its roles in liver cancer cells. CCK-8 assay showed that overexpression of FAXDC2 inhibited the viability of liver cancer cells (HepG2). Flow cytometry analysis indicated that HepG2 cells with overexpressing FAXDC2 showed an S phase arrest, associated with cyclin-dependent kinase 2 decreased. Transwell experiments showed that increasing FAXDC2 inhibited HepG2 cell invasion ability, accompanied by the upregulation of E-cadherin. Notably, knockdown of FAXDC2 had no significant effect on cell cycle and invasion functions. Based on the cBioPortal platform, FAXDC2 was predicted to closely correlate to the ERK signal in tumorigenesis. Western blotting results showed that overexpression of FAXDC2 decreased the phosphorylation level of ERK in liver cancer cells. The present study first identified FAXDC2 as a liver cancer suppressor, which might inhibit the proliferation and invasion of liver cancer cells through the mechanism associated with ERK signaling. The present study provided a possible new target for the diagnosis and treatment of liver cancer. |
doi_str_mv | 10.3892/etm.2023.12315 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10728893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A783585177</galeid><sourcerecordid>A783585177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-22d5a77337bab11b81a8bfb0be67cad8fe890ae003209a1a4c5fccb05c15e60d3</originalsourceid><addsrcrecordid>eNptkc9qGzEQxkVoSYKTa49loWe7Gsna1Z6KcfOnECiBBnoTknYUK-xKjrQ25G3yLHmyyo1rUoh0GEnzzceMfoR8AjrjsmVfcRxmjDI-A8ZBHJFTaFo2BQriw_5MWwkn5DznB1qWqEFKcUxOuAQmeM1Oye3l4vf3Jat8WHnjx1yNK6zWKfbeYdKjj6HSoSvprc67S3TVajPoUPV-i6myOtgSrnF9xV6eLfZ9PiMfne4znu_jhNxdXvxaXk9vfl79WC5uppY3ME4Z64RuGs4bow2AkaClcYYarBurO-lQtlQjpZzRVoOeW-GsNVRYEFjTjk_It1ff9cYM2FkMY9K9Wic_6PSkovbq_0zwK3Uftwpow6RseXH4sndI8XGDeVQPcZNCaVqxFuYC6nn53IPqXveofHCxuNnBZ6sWjeRCCihjTMjsHVXZHQ7exoDOl_f3CmyKOSd0h86Bqh1dVeiqHV31l24p-Px23oP8H0v-B7_Sn_E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2914516402</pqid></control><display><type>article</type><title>FAXDC2 inhibits the proliferation and invasion of human liver cancer HepG2 cells</title><source>PubMed Central</source><creator>Peng, Zhilin ; Xu, Siting ; Zhang, Qing ; Yang, Xueting ; Yuan, Wuzhou ; Wang, Yuequn ; Li, Yongqing ; Zhu, Ping ; Wu, Xiushan ; Jiang, Zhigang ; Li, Fang ; Fan, Xiongwei</creator><creatorcontrib>Peng, Zhilin ; Xu, Siting ; Zhang, Qing ; Yang, Xueting ; Yuan, Wuzhou ; Wang, Yuequn ; Li, Yongqing ; Zhu, Ping ; Wu, Xiushan ; Jiang, Zhigang ; Li, Fang ; Fan, Xiongwei</creatorcontrib><description>The reprogramming of lipid metabolism serves an important role in occurrence and development of liver cancer. Fatty acid hydroxylase domain containing 2 (FAXDC2) is a hydroxylase involved in the synthesis of cholesterol and sphingomyelin and downregulated in various types of cancer. There are no reports on the relationship between FAXDC2 and liver carcinogenesis. The present study used multiple portals and publicly available tools to explore its correlation with liver cancer. The results showed that the expression of FAXDC2 decreased in liver cancer and the methylation level near the promoter increased. Patients with liver cancer and with low expression of FAXDC2 had a poor prognosis. Gain of function and loss of function strategies were performed to evaluate its roles in liver cancer cells. CCK-8 assay showed that overexpression of FAXDC2 inhibited the viability of liver cancer cells (HepG2). Flow cytometry analysis indicated that HepG2 cells with overexpressing FAXDC2 showed an S phase arrest, associated with cyclin-dependent kinase 2 decreased. Transwell experiments showed that increasing FAXDC2 inhibited HepG2 cell invasion ability, accompanied by the upregulation of E-cadherin. Notably, knockdown of FAXDC2 had no significant effect on cell cycle and invasion functions. Based on the cBioPortal platform, FAXDC2 was predicted to closely correlate to the ERK signal in tumorigenesis. Western blotting results showed that overexpression of FAXDC2 decreased the phosphorylation level of ERK in liver cancer cells. The present study first identified FAXDC2 as a liver cancer suppressor, which might inhibit the proliferation and invasion of liver cancer cells through the mechanism associated with ERK signaling. The present study provided a possible new target for the diagnosis and treatment of liver cancer.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2023.12315</identifier><identifier>PMID: 38125362</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Adapter proteins ; Antibodies ; Apoptosis ; Care and treatment ; Cell cycle ; Cholesterol ; Development and progression ; Extracellular signal-regulated kinases ; Fatty acid desaturases ; Fatty acids ; Gene expression ; Genomes ; Genomics ; Health aspects ; Lipids ; Liver cancer ; Medical prognosis ; Membranes ; Metabolism ; Oxidation ; Phosphorylation ; Physiological aspects ; Signal transduction</subject><ispartof>Experimental and therapeutic medicine, 2024-01, Vol.27 (1), p.27, Article 27</ispartof><rights>Copyright: © Peng et al.</rights><rights>COPYRIGHT 2024 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2024</rights><rights>Copyright: © Peng et al. 2023</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c371t-22d5a77337bab11b81a8bfb0be67cad8fe890ae003209a1a4c5fccb05c15e60d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728893/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728893/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38125362$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Zhilin</creatorcontrib><creatorcontrib>Xu, Siting</creatorcontrib><creatorcontrib>Zhang, Qing</creatorcontrib><creatorcontrib>Yang, Xueting</creatorcontrib><creatorcontrib>Yuan, Wuzhou</creatorcontrib><creatorcontrib>Wang, Yuequn</creatorcontrib><creatorcontrib>Li, Yongqing</creatorcontrib><creatorcontrib>Zhu, Ping</creatorcontrib><creatorcontrib>Wu, Xiushan</creatorcontrib><creatorcontrib>Jiang, Zhigang</creatorcontrib><creatorcontrib>Li, Fang</creatorcontrib><creatorcontrib>Fan, Xiongwei</creatorcontrib><title>FAXDC2 inhibits the proliferation and invasion of human liver cancer HepG2 cells</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>The reprogramming of lipid metabolism serves an important role in occurrence and development of liver cancer. Fatty acid hydroxylase domain containing 2 (FAXDC2) is a hydroxylase involved in the synthesis of cholesterol and sphingomyelin and downregulated in various types of cancer. There are no reports on the relationship between FAXDC2 and liver carcinogenesis. The present study used multiple portals and publicly available tools to explore its correlation with liver cancer. The results showed that the expression of FAXDC2 decreased in liver cancer and the methylation level near the promoter increased. Patients with liver cancer and with low expression of FAXDC2 had a poor prognosis. Gain of function and loss of function strategies were performed to evaluate its roles in liver cancer cells. CCK-8 assay showed that overexpression of FAXDC2 inhibited the viability of liver cancer cells (HepG2). Flow cytometry analysis indicated that HepG2 cells with overexpressing FAXDC2 showed an S phase arrest, associated with cyclin-dependent kinase 2 decreased. Transwell experiments showed that increasing FAXDC2 inhibited HepG2 cell invasion ability, accompanied by the upregulation of E-cadherin. Notably, knockdown of FAXDC2 had no significant effect on cell cycle and invasion functions. Based on the cBioPortal platform, FAXDC2 was predicted to closely correlate to the ERK signal in tumorigenesis. Western blotting results showed that overexpression of FAXDC2 decreased the phosphorylation level of ERK in liver cancer cells. The present study first identified FAXDC2 as a liver cancer suppressor, which might inhibit the proliferation and invasion of liver cancer cells through the mechanism associated with ERK signaling. The present study provided a possible new target for the diagnosis and treatment of liver cancer.</description><subject>Adapter proteins</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cholesterol</subject><subject>Development and progression</subject><subject>Extracellular signal-regulated kinases</subject><subject>Fatty acid desaturases</subject><subject>Fatty acids</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Health aspects</subject><subject>Lipids</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Membranes</subject><subject>Metabolism</subject><subject>Oxidation</subject><subject>Phosphorylation</subject><subject>Physiological aspects</subject><subject>Signal transduction</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkc9qGzEQxkVoSYKTa49loWe7Gsna1Z6KcfOnECiBBnoTknYUK-xKjrQ25G3yLHmyyo1rUoh0GEnzzceMfoR8AjrjsmVfcRxmjDI-A8ZBHJFTaFo2BQriw_5MWwkn5DznB1qWqEFKcUxOuAQmeM1Oye3l4vf3Jat8WHnjx1yNK6zWKfbeYdKjj6HSoSvprc67S3TVajPoUPV-i6myOtgSrnF9xV6eLfZ9PiMfne4znu_jhNxdXvxaXk9vfl79WC5uppY3ME4Z64RuGs4bow2AkaClcYYarBurO-lQtlQjpZzRVoOeW-GsNVRYEFjTjk_It1ff9cYM2FkMY9K9Wic_6PSkovbq_0zwK3Uftwpow6RseXH4sndI8XGDeVQPcZNCaVqxFuYC6nn53IPqXveofHCxuNnBZ6sWjeRCCihjTMjsHVXZHQ7exoDOl_f3CmyKOSd0h86Bqh1dVeiqHV31l24p-Px23oP8H0v-B7_Sn_E</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Peng, Zhilin</creator><creator>Xu, Siting</creator><creator>Zhang, Qing</creator><creator>Yang, Xueting</creator><creator>Yuan, Wuzhou</creator><creator>Wang, Yuequn</creator><creator>Li, Yongqing</creator><creator>Zhu, Ping</creator><creator>Wu, Xiushan</creator><creator>Jiang, Zhigang</creator><creator>Li, Fang</creator><creator>Fan, Xiongwei</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>FAXDC2 inhibits the proliferation and invasion of human liver cancer HepG2 cells</title><author>Peng, Zhilin ; Xu, Siting ; Zhang, Qing ; Yang, Xueting ; Yuan, Wuzhou ; Wang, Yuequn ; Li, Yongqing ; Zhu, Ping ; Wu, Xiushan ; Jiang, Zhigang ; Li, Fang ; Fan, Xiongwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-22d5a77337bab11b81a8bfb0be67cad8fe890ae003209a1a4c5fccb05c15e60d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adapter proteins</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cholesterol</topic><topic>Development and progression</topic><topic>Extracellular signal-regulated kinases</topic><topic>Fatty acid desaturases</topic><topic>Fatty acids</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Health aspects</topic><topic>Lipids</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Membranes</topic><topic>Metabolism</topic><topic>Oxidation</topic><topic>Phosphorylation</topic><topic>Physiological aspects</topic><topic>Signal transduction</topic><toplevel>online_resources</toplevel><creatorcontrib>Peng, Zhilin</creatorcontrib><creatorcontrib>Xu, Siting</creatorcontrib><creatorcontrib>Zhang, Qing</creatorcontrib><creatorcontrib>Yang, Xueting</creatorcontrib><creatorcontrib>Yuan, Wuzhou</creatorcontrib><creatorcontrib>Wang, Yuequn</creatorcontrib><creatorcontrib>Li, Yongqing</creatorcontrib><creatorcontrib>Zhu, Ping</creatorcontrib><creatorcontrib>Wu, Xiushan</creatorcontrib><creatorcontrib>Jiang, Zhigang</creatorcontrib><creatorcontrib>Li, Fang</creatorcontrib><creatorcontrib>Fan, Xiongwei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Zhilin</au><au>Xu, Siting</au><au>Zhang, Qing</au><au>Yang, Xueting</au><au>Yuan, Wuzhou</au><au>Wang, Yuequn</au><au>Li, Yongqing</au><au>Zhu, Ping</au><au>Wu, Xiushan</au><au>Jiang, Zhigang</au><au>Li, Fang</au><au>Fan, Xiongwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FAXDC2 inhibits the proliferation and invasion of human liver cancer HepG2 cells</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>27</volume><issue>1</issue><spage>27</spage><pages>27-</pages><artnum>27</artnum><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>The reprogramming of lipid metabolism serves an important role in occurrence and development of liver cancer. Fatty acid hydroxylase domain containing 2 (FAXDC2) is a hydroxylase involved in the synthesis of cholesterol and sphingomyelin and downregulated in various types of cancer. There are no reports on the relationship between FAXDC2 and liver carcinogenesis. The present study used multiple portals and publicly available tools to explore its correlation with liver cancer. The results showed that the expression of FAXDC2 decreased in liver cancer and the methylation level near the promoter increased. Patients with liver cancer and with low expression of FAXDC2 had a poor prognosis. Gain of function and loss of function strategies were performed to evaluate its roles in liver cancer cells. CCK-8 assay showed that overexpression of FAXDC2 inhibited the viability of liver cancer cells (HepG2). Flow cytometry analysis indicated that HepG2 cells with overexpressing FAXDC2 showed an S phase arrest, associated with cyclin-dependent kinase 2 decreased. Transwell experiments showed that increasing FAXDC2 inhibited HepG2 cell invasion ability, accompanied by the upregulation of E-cadherin. Notably, knockdown of FAXDC2 had no significant effect on cell cycle and invasion functions. Based on the cBioPortal platform, FAXDC2 was predicted to closely correlate to the ERK signal in tumorigenesis. Western blotting results showed that overexpression of FAXDC2 decreased the phosphorylation level of ERK in liver cancer cells. The present study first identified FAXDC2 as a liver cancer suppressor, which might inhibit the proliferation and invasion of liver cancer cells through the mechanism associated with ERK signaling. The present study provided a possible new target for the diagnosis and treatment of liver cancer.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>38125362</pmid><doi>10.3892/etm.2023.12315</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1792-0981 |
ispartof | Experimental and therapeutic medicine, 2024-01, Vol.27 (1), p.27, Article 27 |
issn | 1792-0981 1792-1015 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10728893 |
source | PubMed Central |
subjects | Adapter proteins Antibodies Apoptosis Care and treatment Cell cycle Cholesterol Development and progression Extracellular signal-regulated kinases Fatty acid desaturases Fatty acids Gene expression Genomes Genomics Health aspects Lipids Liver cancer Medical prognosis Membranes Metabolism Oxidation Phosphorylation Physiological aspects Signal transduction |
title | FAXDC2 inhibits the proliferation and invasion of human liver cancer HepG2 cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A27%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FAXDC2%20inhibits%20the%20proliferation%20and%20invasion%20of%20human%20liver%20cancer%20HepG2%C2%A0cells&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=Peng,%20Zhilin&rft.date=2024-01-01&rft.volume=27&rft.issue=1&rft.spage=27&rft.pages=27-&rft.artnum=27&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2023.12315&rft_dat=%3Cgale_pubme%3EA783585177%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2914516402&rft_id=info:pmid/38125362&rft_galeid=A783585177&rfr_iscdi=true |